Abstract: Detecting an end-point of user's voice command or utterance with high accuracy is critical in automatic speech recognition (ASR)-based human machine interface. If an ASR system incorrectly detects an end-point of utterance and transmits this incomplete sentence to other processing blocks for further processing, it is likely the processed result would lead to incorrect interpretation. A method includes selecting a first semantic network based on context of the audio signal and more accurately detecting the end-point of user's utterance included in the audio signal based on the first semantic network and also based on at least one timeout threshold associated with the first semantic network.

Abstract: Detecting an end-point of user's voice command or utterance with high accuracy is critical in automatic speech recognition (ASR)-based human machine interface. If an ASR system incorrectly detects an end-point of utterance and transmits this incomplete sentence to other processing blocks for further processing, it is likely the processed result would lead to incorrect interpretation. A method includes selecting a first semantic network based on context of the audio signal and more accurately detecting the end-point of user's utterance included in the audio signal based on the first semantic network and also based on at least one timeout threshold associated with the first semantic network.

Abstract: Detecting an end-point of user's voice command or utterance with high accuracy is critical in automatic speech recognition (ASR)-based human machine interface. If an ASR system incorrectly detects an end-point of utterance and transmits this incomplete sentence to other processing blocks for further processing, it is likely the processed result would lead to incorrect interpretation. A method includes selecting a first semantic network based on context of the audio signal and more accurately detecting the end-point of user's utterance included in the audio signal based on the first semantic network and also based on at least one timeout threshold associated with the first semantic network.

Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Abstract: The present invention relates to an improved process for the preparation of pyrroles derivatives having hypolipidemic and hypocholesteremic activities. In particular, the invention relates to an improved process for the preparation of 2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also relates to an improved process for the preparation of mesylate compound (A1).

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.

Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.

Abstract: The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I?) and monohydrate of Formula (I),

Abstract: The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclohexylmethanisoindol-1,3-dione and intermediates thereof.

Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention relates to an improved process for the preparation of pyrroles derivatives having hypolipidemic and hypocholesteremic activities. In particular, the invention relates to an improved process for the preparation of 2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also relates to an improved process for the preparation of mesylate compound (A1).

Abstract: The invention provides an amorphous form of dapagliflozin 1,2-propanediol of Formula (A) or hydrates thereof and their process for preparation. The present invention also provides a pharmaceutical composition comprising art amorphous solid dispersion containing dapagliflozin 1,2-propanediol or hydrates thereof.

Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.

Abstract: The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I?) and monohydrate of Formula (I),

Abstract: The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexyl-methan-isoindol-1,3-dione and intermediates thereof.

Abstract: A process for the preparation of n-heneicosane is disclosed. The process comprises (a) reacting 2,4-alkaneanedione with 1-bromooctadecane in absolute ethanol in the presence of 18-crown-6 as catalyst to produce 2-heneicosanone; and (b) reducing said 2-heneicosanone using hydrazine hydrate and potassium hydroxide in ethylene glycol to obtain n-heneicosane.